Booking.com

US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapy

Booking.com

Stockholm , Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I study to investigate the safety and tolerability of a combination treatment of birinapant and radiation therapy in patients with recurrent Head and Neck Squamous Cell Carcinoma (HNSCC). The initiative for the study came from researchers at the US National Cancer Institute (NCI). The study is sponsored and financed as part of NCI’s Cancer Therapy Evaluation Program (CTEP). Medivir provides birinapant and will be afforded full access to all reports from the study under

Source: US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapy

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.